background: Assessment of male fertility is traditionally based on microscopic evaluation of semen. However, the classical semen parameters do not adequately reflect sperm function, and their clinical value in predicting fertility is limited. We hypothesize that the sperm expression profile could reflect the fertilizing quality of spermatozoa and could be more informative for predicting the in vivo reproductive fitness of men with normal semen parameters. results: Significant differences in the expression of individual genes were observed between groups of donors with the lowest and highest pregnancy rates (PRs) after IUI. Additionally, we have developed a molecular means to classify the fertility status of semen donors for IUI based on the expression signature of four genes. In the Phase I study, this model had 90% sensitivity and 97% specificity for discriminating donors resulting in low PRs (cut-off value: ,13.6%), far better than that obtained from the combination of sperm parameters. The translation of the model was validated in Phase II donors resulting in a sensitivity of 71.5% and a specificity of 78%.
Introduction
Assessment of male fertility is based on the descriptive information provided by the basic semen analysis including sperm count, motility and morphology. New threshold values for semen parameters have been recently updated (Cooper et al., 2010) using men who had produced a recent pregnancy as reference individuals. However, despite a clear correlation between semen quality and the probability of conception (Guzick et al., 2001) , the wide overlap of measurements between fertile and infertile men suggest that semen analysis has a limited power to predict fecundity and to diagnose male infertility (Bartoov et al., 1993) . The significant proportion of couples with unexplained infertility suggests that abnormal sperm function can be due to molecular defects in some cases (Lewis, 2007) . Many efforts have been made to build up new diagnostic tests to provide more accurate information on the fertilizing potential of human spermatozoa (Samplaski et al., 2010) , but none of them have yet met the requirements to be adopted for clinical purposes.
Spermatozoa contain, besides the haploid genetic material, an abundant number of functionally viable transcripts (Ostermeier et al., 2002; Krawetz, 2005; Zhao et al., 2006) , commonly considered as remnants of stored mRNA from post-meiotically active genes, reflecting the accurate development of spermatogenesis (review in Miller and Ostermeier, 2006) . However, the potential for active post-meiotic production of transcripts exists; a persistence of a low but detectable level of transcription and translation in mature sperm cells had been described (Miteva et al., 1995; Naz, 1998; Gur and Breitbart, 2006) . Furthermore, human spermatozoa can deliver mRNA to the oocyte during fertilization (Ostermeier et al., 2004) . Some of these mRNAs have been shown to be translated de novo in the oocyte after fertilization, supporting the hypothesis that at least some transcripts might have a function during or beyond the process of fertilization (Braude et al., 1988; Siffroi and Dadoune, 2001; Gur and Breitbart, 2006) and also contribute to the early transcriptome of the embryo (Boerke et al., 2007) .
It has been suggested that sperm mRNAs present in the ejaculated spermatozoa represent a genetic fingerprint, and could be considered to be a historical record of what happened in gene expression during spermatogenesis (Zhao et al., 2006) . Some studies have reported differences in the amount of certain sperm transcripts between infertile and fertile men (Steger et al., 2008; Avendano et al., 2009) . A different expression signature was also determined related to the differences in sperm concentration (Guo et al., 2007) , motility (Carreau et al., 2007) and morphology (Platts et al., 2007) . Interestingly, differences in the expression of a few hundreds of transcripts between fertile and infertile men with normal semen parameters have been described recently (Garrido et al., 2009) . However, there has been no formal study that assesses the diagnostic efficiency of sperm RNA expression in comparison to classic semen parameters.
Assisted reproduction techniques (ARTs) have revolutionized the treatment of infertile couples. Among them, therapeutic donor insemination (TDI) of sperm provides an ideal first approach to achieve pregnancy in couples with a severe male infertility factor. Despite having apparently normal semen characteristics, some sperm donors have low pregnancy rates (PRs) after TDI (Marshburn et al., 1992; Johnston et al., 1994) , a situation analogous to the male partner in couples with unexplained infertility. We hypothesize that the assessment of the sperm gene expression profile could reflect the fertilizing quality of spermatozoa and could also be informative in predicting in vivo reproductive fitness of men with normal semen parameters. To address this issue, we have studied a cohort of semen donors with good semen quality and with a detailed record of reproductive outcome using intrauterine insemination (IUI) in different female recipients. Recruitment of semen donors was carried out among young university students with unknown fertility status at the time of donation, so they were representative of the normozoospermic general population. We believe that this approach is suitable for investigating the molecular features of unexplained male infertility, because it circumvents some of the shortcomings present when studying infertile couples in general, such as the confounding role of the significant proportion of female causes that contribute to reproductive failure.
Materials and Methods

Experimental design
The study was divided into two phases. In Phase I, or the training phase, a general overview of gene expression behaviour was determined in relation to the PR obtained by sperm donors and a gene set expression signature was obtained. In Phase II, we validated the gene set signature as a predictive diagnostic tool in an independent series of donor semen samples. The study was approved by the Institutional Review Board of the Centre.
Selection of semen donors
Recruitment of candidate donors was carried out among university students, most of whom had not attempted procreation at the time of assessment. The clinical procedures for screening semen donors were done at the Andrology Service of the Fundació Puigvert, and included full personal and familiar medical history to rule out heritable conditions, physical examination and a minimum of two semen analyses [performed in accordance with the World Health Organization guidelines (WHO, 1999) except for motility assessments that were done at room temperature]. Spermiograms included volume, pH, sperm concentration, four-category motility assessment, vitality, morphology and antisperm antibodies. Motility and sperm count were done in duplicate aliquots of ≥200 cells, and measures were adopted to control for acceptable differences between duplicates. Sperm concentration was performed on diluted, immobilized samples using haemocytometer chambers. Computer-assisted sperm analysis (CASA) was performed on fresh ejaculates with a Hamilton-Thorn 2030 system (software version 6.4) to obtain objective measurements of sperm kinematics (Pedigo et al., 1989) . Serological tests for HIV I and II, hepatitis B and C, cytomegalovirus and syphilis were done at baseline, at the end of the donations and again after 6 months of quarantine; only donors who tested negative were used. Karyotype analysis was done in donors enrolled after the year 2000. Donors were allowed to give 6 -12 donations. Semen parameters of each individual donation were measured to monitor semen quality relative to the baseline assessment. Donors with deteriorating semen quality were discontinued before completing their donations.
All semen samples were frozen within 2 h of collection in an equal volume of glycerol-egg-yolk-citrate cryopreservative medium (Sperm Freezing medium, Irvine Scientific, Santa Ana, CA, USA) in vapours of liquid nitrogen using 1.8 ml cryovials, and stored at 21968C until needed. Cryosurvival was assessed as the percent progressive motility of sperm after thawing in a 378C bath.
Our study recruited a total of 68 normozoospermic donors. The inclusion criteria were as follows: (i) having at least four surplus frozen aliquots (0.5 ml straws) available after the use of insemination purposes, (ii) average sperm concentration ≥40 millions/ml; progressive motility ≥30%, normal morphology ≥7% at the time of initial assessment, (iii) .10 insemination cycles per sperm donor performed to a minimum of 6 female recipients and (iv) not being discontinued due to impairment of semen quality during their donation period. All donors were of Caucasian origin.
Approximately 2/3 of donors (n ¼ 43) were randomly chosen for the training Phase I gene expression analysis. These donors were divided into study groups: 1, 2 or 3 (tertiles) according to the PR obtained with their sperm. Semen samples from the remainder of the individuals (n ¼ 25) were used for validating Phase II (Fig. 1) .
Female recipients and insemination procedures
Women entering the TDI program at the Fundació Puigvert who were inseminated with samples from the selected donors during the period 1994 -2006 were considered for this study. Eligibility for insemination included severe male factor in the majority of cases, and ejaculatory disturbances or hereditary conditions in the husband. Ovulatory status was studied by biphasic temperature charts and progesterone at the mid-luteal phase, and a normal hysterosalpingography was required before inseminations.
Prior to IUI, in all cases, mild follicular stimulation was induced with 75 UI/day of gonadotrophins (Neo-Fertinorm or Pergonal, Serono, SA, Spain) , and monitored by analysis of estradiol and transvaginal ultrasonography. Ovulation was induced by 10 000 UI of hCG (Profasi, HCG Lepori) when at least one follicle of .18 mm was observed. Thawed semen samples (0.5 ml) were diluted with 2 ml of Ham's F-10 medium with 0.5% HSA and prepared by differential centrifugation using 90 and 65% density gradients (Percoll, Pharmacia, Sweden, or Puregon, Vitrolife, Denmark) as described elsewhere (Ruiz-Romero et al., 1995) . The final volume was adjusted to 0.4 ml. Inseminations of sperm were done on 2 consecutive days, 24 and 48 h after the administration of hCG using an insemination catheter (#4220, Gynétics Medical, Lommel, Belgium). If b-hCG levels were increased 2 -4 weeks after the insemination, pregnancy was confirmed by ultrasound scan. The selection of semen donors for insemination was performed by the medical staff on the basis of a matching phenotype of the husband. The semen donor for a particular woman was changed after two or three insemination cycles if pregnancy had not occurred. Donors failing to produce pregnancies were eventually discarded from further use after 25-50 cycles of treatment.
RNA extraction and cDNA synthesis
In order to enrich for fertile spermatozoa and remove somatic contaminants from the expression analysis, the four frozen-thawed semen samples from each donor were individually purified by a centrifugation through discontinuous density gradients (65-90%) using a technical procedure similar to that used for IUI (Ruiz-Romero et al., 1995).
Total RNA for each donor was obtained from the pool of the gradientpurified spermatozoa using NucleoSpinw RNA II Kit (Macherey-Nagel, Duren, Germany), according to the instructions provided by the manufacturer with minor modifications. Briefly, lysis buffer was added to the samples at 600 ml/10 7 cells. The lysates were homogenized with a 20-gauge needle and heated for 30 min at 608C. The process then continued with
Step 4 of the kit, including a DNase digestion step. RNA purity and integrity were assessed by RT of 200 ng of RNA, using a Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and a subsequent PCR using the intron spanning PRM2 primers as previously described (Ostermeier et al., 2005) . As previously shown, the sole existence of the intronless PRM2 amplicon (148 bp) verified the RNA integrity and showed that the preparations were free of genomic DNA (gDNA; that would generate a 310 bp intron spanning amplicon). The removal efficiency of somatic and immature germ cell was confirmed by the absence of PTPRC (highly expressed in blood cells), CDH1 (highly expressed in epithelial cells) and SYCP3 and MSH4 (both expressed in meiotic germ cells) expression in our RNA samples (Fig. 2 ). SYCP3 and MSH4 primer sequences and conditions of amplification were used as published (Terribas et al., 2010) . Gene-specific primer sets for PTPRC (PTPRC-F: aaaagtgcaacgtaatggaagt; PTPRC-R: ccagagtatttccagcttcaac) and for CDH1 (CDH1-F: ctggttcagatcaaatccaaca; CDH1-R: attggatcctcaactgcattc) were designed by using the Primer3 software (http://frodo.wi.mit .edu/primer3/). Single-stranded cDNA was obtained by RT of 200 ng of RNA, using the High Capacity cDNA Reverse Transcription Kit (AB, Foster City, CA, USA). Two independent RT reactions were performed from each RNA sample. The resulting cDNA solution was stored at 2208C until use.
Gene expression quantification
Quantitative real-time PCR assays were performed by means of the application of the PCR arrays on microfluidic cards (MFC), using 384-well TaqManw Low Density Arrays (TLDAs) on an Applied Biosystems 7900HT Fast Real-Time PCR System (AB, Foster City, CA, USA). Half of the RT reaction was applied on each port, each connecting to 48 reaction wells. A first approach (TLDA1; Fig. 1 ) was performed on the 96-gene format MFC (95 experimental assays and 1 TLDA amplification control) allowing simultaneous measurement of 87 target genes that were selected based on human spermatozoa cell location from cDNA microarrays (Ostermeier et al., 2002; Zhao et al., 2006) , and 8 ubiquitously expressed genes, commonly used as endogenous control genes to normalize the variability between clinical samples (Vandesompele et al., 2002; De Kok et al., 2005) , as potential reference genes for our study. Only samples from donors of the training phase were analysed by this approach. A subsequent second approach (TLDA2; Fig. 1 ) was performed on the 24-gene format MFC, which included 21 target genes, 2 reference genes and an amplification control. Both training and validating donor samples were analysed by this approach. For training donors, the TLDA2 comprised a different RT reaction of the same donor RNA sample used on the TLDA1 approach. The genes and the corresponding assays on demand used for the set-up of the TLDAs are listed in Supplementary data, Table SI. The design of each assay and its potential gDNA amplification is additionally detailed (Supplementary data, Table SI ). In order to check the assay specificity, and thus to verify that the assay cannot amplify related processed sequences (i.e. processed retroposed pseudogenes), a Blast analysis on human transcript database was performed by using the information of primers and probe sequences of each assay. The primer and probe sequences can be inferred from the assay location (indicates the middle position of the amplicon on the specified RefSeq; this will be the position occupied by the probe), and the amplicon length (5 ′ and 3 ′ sequences of the amplicon will define primer sequences) detailed on the AB assay design (www.appliedbiosystems.com).
Samples from donors with low and high PRs were always analysed as paired samples in the same analytical run in order to exclude between-run variations. Real-time PCR data were pre-processed and stored in SDS 2.2 software (AB, Foster City, CA, USA).
To confirm reproducibility and precision of real-time PCR experiments, the inter-assay variation of samples amplified on both approaches was determined. Variation was measured as the coefficient of variation of C t from the C t mean value of both TLDA approaches. In the above mentioned RT-PCR runs, the inter-assay variation ranged from 0.63 to 1.60% with the exception of PRM1 (2.40%), PRM2 (2.04%), ENO1 (4.13%) and RERE (3.42%), confirming high reproducibility and precision for most of the 23 genes included in the TLDA1 and TLDA2 approaches.
Data analysis
All statistical analyses were performed using the SPSS version 12 (Lead Technologies, Chicago, USA) software. The non-parametric KruskalWallis test was used to analyse the differences in clinical data, absolute Figure 2 RT -PCR analysis of control transcripts for spermatozoal RNA purity and integrity assessment. (A, B, C, and E) Five microlitres of amplified product on a 1% agarose gel and (D) 2.5% agarose gel (nusieve/agarose 3:1). M, molecular weight marker; lanes 1 -4, cDNA from spermatozoa; lane 5a, control testicular cDNA; lane 5b, cDNA control from lymphocytes; lane 5c, cDNA control from colon; lane 6, control DNA from lymphocytes and lane 0, water (negative control). PRM2 and PTPRC primers allow the amplification of both cDNA and gDNA. expression levels of reference genes and relative expression of target genes among the study Groups 1, 2 and 3 of Phase I. Differences in absolute and in relative expression of TLDA1 target genes in patient Group 1 or 2 compared with Group 3 were evaluated by the non-parametric Mann-Whitney U-test.
Expression stability of the gene/s was calculated with the GeNorm program (Vandesompele et al., 2002) , in order to select the most stable reference genes and improve normalization of target genes. GeNorm software calculates the gene expression stability value M of multiple candidate genes as the average pair-wise variation of a particular gene compared with all other candidate reference genes. Lower M values indicate genes with less expression variation among samples.
Raw data normalization was performed with the qBase program (Hellemans et al., 2007) by using one reference gene as well as by applying geometric averaging of two reference genes, in parallel. Relative quantification values were expressed using the 2 2DDCt method as fold changes in the target gene normalized to the reference gene and related to the expression of a control sample. For the training donors, the mean value of the TLDA1 and TLDA2 normalized 2 2DDCt values for each donor were then subjected to evaluation of statistical significance of differential expression among groups (Kruskal -Wallis or Mann -Whitney test as mentioned above).
Pearson product moment correlation coefficients were calculated to correlate the molecular and clinical data of donors. Receiver operating characteristic (ROC) curve analysis of the relative expression values was used for distinguishing those individuals with PR ≤13.6%, which was the cut-off value for the 25 percentile. Accuracy was measured as the area under the ROC curve (AUC). The threshold value was determined by Youden's index, calculated as sensitivity plus specificity 2 1 (Skendzel and Youden, 1970) .
Following the recommendations of the STARD initiative (Bossuyt et al., 2004) , we defined 'positives' as donors showing pathological results (i.e. low PR) and thus, sensitivity corresponded to the proportion of 'infertile donors' successfully detected by a given test (true positive rate), while specificity indicated the 'fertile donors' testing as normal (true negative rate).
Multivariate binary logistic regressions were used for selection of the optimal combination of genes associated with fertilization status of the Phase I donors and for validating the combination of genes as a predictive tool in donors of Phase II. A backward stepwise (conditional) method was used to drop insignificant terms. The multivariate regression model included the genes found to significantly distinguish IUI PR ≤13.6%. The binary logistic regression model provides the following estimation of the logit function:
where p ¼ P (adequate fertility potential for insemination), Logit( p) ¼ log( p/(1 2 p)) ¼ log(odds), B ¼ log OR and Xn ¼ the expression value of the selected genes. Therefore, if we use this estimated model as a prediction model, with the standard classification cutoff of 0.5, we would classify individuals with a positive Logit function estimation as 'adequate for insemination' and individuals with negative Logit function estimation as 'inadequate for insemination'.
Binary logistic regressions of a single genetic variant as well as single/ combination of clinical parameters were calculated for comparison of predictive values of the model.
A P-value ,0.05 was considered significant. False discovery rate (FDR) of significant tests was estimated to overcome false positives overestimation in a multiple testing approach (Storey and Tibshirani, 2003) .
Results
Reproductive results of semen donors
A total of 545 women underwent 1631 IUI cycles with samples from all 68 donors studied. The PR, live birth rate and miscarriage rate of the donors were 17.21, 15.2 and 11.8% respectively.
In order to obtain a general overview of the donor gene expression behaviour related to PR outcome, to support a further and deeper evaluation of its potential as a diagnostic tool, donors selected for the training phase were first classified into three groups (tertiles) according to the PR obtained after IUI: low, from 0 to 15.70% PR (Group 1), medium, from 15.71 to 23.00% PR (Group 2) and high, from 23.01 to 45.0% PR (Group 3; Table I ). The average PR of training donors was 18.4%. Although the number of IUI cycles was similar in the three groups, the number of pregnancies, the PR and the live birth rate were significantly different among groups (Table I) . Clinical features and baseline semen parameters were similar among tertiles. The average concentration of progressive motile spermatozoa used, after gradient selection, at the time of the insemination, showed a tendency toward different values between groups, with a borderline significance (P ¼ 0.058). None of the variables corresponding to the female recipients showed significant differences.
The average PR of the donors included in the validation phase was 15.7% and live birth rate was 14.4%. These reproductive outcomes, as well as the clinical and analytical variables were comparable to those of the training phase (data not shown).
Selection of genes for the TLDA2 approach
The presence of mRNA for 74 out of the 95 genes of the TLDA1 study (genes in bold, Supplementary data, Table SI) was confirmed by RT-PCR in human ejaculated spermatozoa. The remaining genes (n ¼ 21) could not be amplified (C t value .33) under the conditions of the study, suggesting that the transcript levels were beneath the detection threshold of the technique. Of the 74 genes amplified, 35 were excluded for further analysis due to poor amplification efficiency across samples (missing expression values for .80%). The mRNA levels of genes amplified in all the samples of the study (Supplementary data, Table SI) were further evaluated (n ¼ 39; Fig. 1) .
In order to achieve precise and reliable quantitative expression results of the genes under consideration, the measurement of gene expression by real-time RT-PCR requires at least one proper internal control reference gene for normalization purposes. None of the eight genes previously used as endogenous control genes have quantifiable expression values, so they were excluded as normalizers for our study. Therefore, from the 39 genes, we selected those showing stable expression levels in the samples investigated to be subsequently used as normalizers or reference genes. For this purpose, we used the GeNorm program that selected the RPS17 and RPL29 as the most stably expressed genes (M ¼ 0.038 for both genes). Additionally, we ascertained that these genes were not differentially expressed among the groups of the study (P . 0.05). These two genes were included in the TLDA2 approach as reference genes.
The selection of target genes included in the TLDA2 approach (Supplementary data, Table SI) was performed by taking into account those genes that presented statistical differences in C t values between Groups 1 and 3.
Relative gene expression profile of donor sperm
Once the TLDA1 and TLDA2 C t data from the training donor samples were obtained, the quantification of the 21 target gene mRNA levels was expressed as relative transcript levels, using RPS17 as a single reference gene as well as the RPS17 and RPL29 gene combination reference value, for both TLDA experiments.
When training donors were classified into tertiles according to the IUI PR, we found eight differentially expressed genes among the three groups: RPL23A, RPS27A, RPS8 (P ≤ 0.01), RBM9, RPS27, RPS3, TOMM7 and RPS18 (P ≤ 0.05), when normalized with both single and combination reference genes (Fig. 3) . The FDR value of significant tests was quite small (1.7%). All of them presented small intra-group standard deviation values (0.08-0.30).
RPL23A, RPS27A, RPS3, RPS8 and TOMM7 genes showed a significant fold-change decrease in Group 1 of 1.22 (P ¼ 0.001), 1.39 (P ¼ 0.0002), 1.22 (P ¼ 0.004), 1.13 (P ¼ 0.005) and 1.26 (P ¼ 0.026), respectively, when compared with Group 3 (Fig. 3) .
The FDR value was 0.082 implying that 8.2% of significant tests will result in false positives. Interestingly, RPL23A, RPS27A, RPS3, RPS8 and TOMM7 showed a linear tendency among the three groups of the study.
Since, data normalization using both single and combination of reference genes resulted in the same statistical data; gene expression data normalized with RPS17 were subsequently used to simplify the model.
Correlation study between gene expression profiles and semen parameters or PR
No significant correlation was found between the sperm baseline concentration or motility semen parameters and the relative mRNA expression levels of any of the 21 genes analysed. However, morphology of spermatozoa was found to be positively correlated with FOXG1 (r: 0.341; P ¼ 0.025) and RPS8 (r: 0.371; P ¼ 0.014) transcript levels. When assessing the sperm parameters post-thaw, significant correlations were found between the percentage of post-thaw Contingency three-by-two tables with significance calculation using the Yates correction of chi-square test and the Fisher test to the 5% limit. Significant differences (P , 0.05) are indicated in bold.
d,e,f n ¼ 11, n ¼ 12 and n ¼ 14.
motile sperm and EIF5A (r:0.355; P ¼ 0.019), RPL13 (r: 0.397; P ¼ 0.008), RPL23A (r: 0.346; P ¼ 0.023), RPL7 (r: 20.353; P ¼ 0.020), RPS18 (r: 20.390; P ¼ 0.010) and RPS6 (r: 20.337; P ¼ 0.027) as well as between the post-thaw motile sperm count and RPS18 (r: 20.326; P ¼ 0.033) and RPS27 (r: 20.345; P ¼ 0.024). In order to investigate a possible association between gene expression and the PR and to confirm whether the results could be of physiological and/or clinical relevance, we performed a correlation study between the normalized gene expression ratios and the PR mean value of the insemination cycles in which the donor sample was used. Significant positive correlation coefficients were found between PR and the transcription levels of six genes: RPL23A, RPL4, RPS27A, RPS3, RPS8 and TOMM7 (P , 0.05; Table II ). We performed the same type of analysis for other clinical reproductive parameters such as the birth rate and the miscarriage rate. Three additional genes: RPL10A, RPS6 and RBM9 expression values were found to significantly correlate with miscarriage rate (P ≤ 0.05; Table II) . Similar correlation studies were additionally performed using semen parameters for comparison (Table II) .
We hypothesized that there might be a threshold level of transcripts with the potential for discriminating donors with lower PR. We then selected as the state variable the 25th percentile of PR produced by the donors of the training phase, which was ≤13.6%. The ROC curve analysis of gene expression levels resulted in good predictive accuracy (AUC .0.750) of the expression values of seven genes: EIF5A, RPL13, RPL23A, RPS27A, RPS3, RPS8 and TOMM7 (P , 0.01). Therefore, they were selected as potential genetic biomarkers of sperm function (Table III) . None of the classical semen parameters reached AUC significantly .0.5. The mean of progressively motile sperm inseminated values were excluded from the analysis because this information was obtained at the time of IUI treatment, and thus could not be used as a tool for screening the future fertility of the donors.
Searching for a multiplex model: multivariate logistic regression analysis
To determine if a multiplex model could improve performance over single biomarkers for discriminating donors with ≤13.6% PR, the Figure 3 Expression ratios of target genes, using RPS17 as normalizer, in training donors classified into tertiles according to the IUI PR. Genes with significant differences between groups (P , 0.05, Kruskal -Wallis test) are displayed in (A), and those with non-significant changes are shown in (B). Group 1, black bars; Group 2, grey bars and Group 3, white bars. The gene expression mean value (bars) and 95% CI (error bars Y) are shown.
previously selected genes were analysed in a multivariate regression analysis.
This analysis resulted in a model that included EIF5A, RPL13, RPL23A and RPS27A genes (Table IV) . The sensitivity and the specificity for predicting donors with low IUI PR were 90 and 97%, respectively. The accuracy of the test was corroborated as the calculated AUC was 0.955 (P ¼ 0.000) and the P-value of Hosmer and Lemeshow test was 0.554.
As a comparison, a multivariate regression analysis of all the semen parameters was performed. The resulting model, including the combination of the baseline percentage of progressive motility and postthaw progressive motility count variables, resulted in a sensitivity of 30%, specificity of 94% and AUC of 0.773 (P ¼ 0.010; Table IV) .
The classifier based on gene expression values of Phase I donors was validated in samples of donors of Phase II, resulting in a sensitivity of 71%, a specificity of 78% and the accuracy of 76% (Table IV) . Identification of positive individuals (infertile donors) was more efficient when applying the genetic classifier than when using the semen values. The model with semen parameters in Phase II donors showed a sensitivity of 14% and a specificity of 100% (Table IV) .
When the results of all donors were considered together, the multivariate logistic analysis using the genetic markers showed a true positive rate or sensitivity of 82.3% (14/17), compared with 23.5% (4/17) obtained when using the semen variables. As a consequence, 10 additional positive donors (58.8%) could be detected by using the gene signature. From another point of view, the ability to identify false negatives (subfertile donors testing as normal) was better with the genetic approach: the probability of normality [ p(D2)] after a negative result increased to 94% from a pre-test probability of 75% (incremental gain of 19%), whereas the p(D2) gain was only 4% with semen parameters (Fig. 4) .
Discussion
Despite having normal sperm parameters, differences in the fecundity of donor sperm are observed after insemination therapies (Marshburn et al., 1992; Thyer et al., 1999; Navarrete et al., 2000) . Classical sperm variables at the time of baseline evaluation of donors have limited value for predicting their reproductive fitness for insemination therapies (Sidhu et al., 1997; Freour et al., 2009) . Thus, close supervision of the clinical results obtained by each donor is the only pragmatic way to discard those who show poor PR after a reasonable number of insemination cycles (Johnston et al., 1994) . Some studies suggest that characteristics of the thawed samples used in the insemination (number of motile sperm, kinetic or morphometric parameters measured with CASA systems) are able to improve the accuracy of pregnancy outcome (Marshburn et al., 1992; Macleod and Irvine, 1995; Freour et al., 2009) in comparison with the baseline assessments. However, these measurements made on individual samples are of limited utility for the purpose of deciding if a candidate man can be accepted as a valid semen donor. Other approaches to improve the assessment of donor fecundity are based on multiparametric analysis of semen characteristics (Allamaneni et al., 2004) or a number of sperm function tests (Richardson and Aitken, 1993) . However, the diagnostic performance of these methods is modest due to the low sensitivity of the results obtained.
In this report, we have developed a molecular means to classify the fertility status of semen donors for IUI based on gene expression profiles of sperm. Our experimental approach was the selection of the gene set expression panel in a training series of semen donors with a detailed record of IUI reproductive outcomes in different female recipients. The potential of the gene panel as a predictive classifier was validated in an independent series of donors. The sensitivity value of the genetic model (EIF5A, RPL13, RPL23A and RPS27A genes) as a predictive tool for discriminating donors with low IUI PR was far better than that obtained from the combination of traditional sperm parameters. As a result, 59% of positive (subfertile) donors effectively detected by the gene signature approach were wrongly classified as negative (fertile) with the semen variables. It is generally accepted that a diagnostic test for male infertility in couples attempting pregnancy should have high specificity, reducing false positives (fertile men testing as abnormal) in order to avoid the over-treatment of couples with aggressive and costly techniques such as IVF and ICSI. However, in the case of deciding if a donor with normal semen parameters is likely to produce pregnancy the situation changes. In this case, all parties involved in the process of artificial insemination with donor sperm are interested in achieving the highest possible PRs. Therefore, it is preferable to have a test with high sensitivity, identifying those donors that produce low PR to prevent the subsequent use of their semen samples, even at the price of discarding few fertile donors if specificity becomes suboptimal. A similar scenario is found in couples with unexplained infertility, although in this case, the expected probability of male subfertility is likely to be higher. There is insufficient evidence to know the relative effectiveness of IUI and IVF/ICSI in couples with unexplained fertility problems (NICE, 2004) . Although husband IUI has been widely used as an empirical treatment for unexplained infertility (Verhulst et al., 2006) , some couples with hidden defects in sperm function will not become pregnant, and will have to undergo IVF/ICSI. Conversely, it is possible that low-tech treatment would be enough to produce pregnancy for some of those patients who go directly to IVF/ICSI (Collins, 2003) . Hence, a prognostic marker to estimate the chances for fertility treatment could help physicians in counselling about the best treatment for patients. In this context, the test described here would be able to select more men who show reduced fertility potential, and will benefit from early referral to IVF/ICSI, avoiding unsuccessful alternatives such as expectant management or husband IUI. When the IUI technique is coupled with ovarian stimulation, the sperm cells are placed directly into the uterus at the time of ovulation, bypassing ovulatory alterations and cervical hostility in the recipient women as confounding factors. The effect of additional female factors has been well recognized, and can heavily influence the reproductive outcome of donor insemination (Botchan et al., 2001; De Brucker et al., 2009 ). In our study design, the use of multiple female recipients, with no significant differences in age and gynaecological conditions between the groups with different PRs, reduced the impact of female factors as confounding elements on the donor reproductive outcome. Therefore, we believe that the reproductive differences observed are truly representative of intrinsic properties of the sperm used, which tend to be constant for each donor over the time (Thyer et al., 1999) .
The quality of spermatozoal RNA used in this study, a big concern to studies like this one, had been further examined. Firstly, the absence of genomic fragments in the RT-PCR result for PRM2 Considering pre-test probability of normality (good pregnancy) ¼ 0.75.
confirmed that DNA contamination (visible in some samples when studying PTPRC) is very low, and therefore, unlikely to affect the quantification of strongly transcribed genes such as those studied in this work. Furthermore, the removal efficiency of somatic cells was also taken into account. The lack of amplification of genes such as HPRT, HMBS, PGM1, GUSB, PGK1 and TBP, included in the TLDA1 approach, suggest that these genes, widely used as endogenous genes in somatic tissues (Vandesompele et al., 2002; De Kok et al., 2005) , are poorly expressed in spermatozoa. As far as we know, there is no previous data to suggest expression of these genes in sperm. Altogether, it is an additional indication that the somatic cell contamination is not elevated enough to affect spermatozoal transcript quantification. One of the major drawbacks for the clinical use of sperm gene expression data is the low level of transcripts contained in spermatozoa. PCR amplification on TLDAs was considered an appropriate method for our study and for future potential diagnostic purposes, because it allows the simultaneous quantitative amplification of multiple reactions with minimal cDNA material and a reduced variability due to pipetting. Furthermore, in order to improve experimental accuracy, data were normalized to suitable reference genes, which showed constitutive and stable expression levels in the samples investigated.
Expression differences were previously found in sperm related to spermatozoa motility and capacitation (Lambard et al., 2004) and in sperm transcriptomes from fertile compared with idiopathic infertile men (Avendano et al., 2009; Garrido et al., 2009) . To the best of our knowledge, our study is the first attempt to systematically explore the diagnostic possibilities of sperm mRNA expression patterns. We observed significant differences in the expression of some individual genes RPL23A, RPS27A, RPS3, RPS8 and TOMM7 between sperm samples from donors with the worst and the best PR after IUI assisted reproduction. Interestingly, one of these genes, RPS3, was found to be differentially expressed between men of proven fertility and men with idiopathic infertility in a previous study (Garrido et al., 2009) . Hence, description of the normozoospermic sperm transcriptome could also be helpful to identify genes or gene pathways responsible for idiopathic infertility.
In conclusion, our findings contribute to the task of selecting the best genetic markers for use for the prediction of the fecundity ability of spermatozoa. This will lead to an improvement in the pregnancy outcome of the assisted reproduction. We have shown an expression fingerprint related to the fertilizing ability of sperm when used in therapeutic IUI that could complement semen analysis as a fertility test with several therapeutic uses. These include selection of those samples from donor semen banks appropriate for use for IUI assisted reproduction as well as provision of realistic information about the chances of success of conjugal IUI for couples with unexplained infertility.
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